Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease
Status:
Unknown status
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the trial is to develop Epimedium Prenylflavonoid (EP) extract as a
pharmaceutical-quality intervention for post-menopausal osteoporosis and cardiovascular
disease. There will be 3 cohorts of 10 healthy men each for the Phase 1 study. In each
cohort, 8 men will receive the Epimedium capsules and 2 men will received the matched
controls.